上海医药(601607.SH)：硫酸艾沙康唑原料药上市申请获得批准

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Kangli (Changzhou) Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for the production of Sulfate Isavuconazole active pharmaceutical ingredient [1] Group 1: Company Information - The approved drug, Sulfate Isavuconazole, is a triazole antifungal medication and is a prodrug of Isavuconazole, which is rapidly converted into its active metabolite in the body by plasma esterases [1] - Isavuconazole, like other triazole antifungal drugs, works by inhibiting the biosynthesis of ergosterol, thereby disrupting the formation of fungal cell membranes [1]